| Background: Chronic hepatitis B（CHB）remains one of the most serious public health problems in the world.Currently,the treatment for CHB is mainly antiviral therapy.With the widespread and application of antiviral drugs,HBV DNA replication in liver cells and serum of CHB patients has been greatly inhibited.Thus,it can reduce the occurrence of liver inflammation and necrosis,reverse liver fibrosis,and even effectively delay and reduce the progression and occurrence of some CHBrelated liver failure,cirrhosis and hepatocellular carcinoma,thus improving the quality of life and prolonging the survival time of patients.However,in recent years,it has been found that some patients are still in the stage of low-level viremia（HBV DNA level intermittent or continuous 20-2000IU/ml）after antiviral treatment,and relevant studies have shown that hypoviemia may lead to the further development of cirrhosis and is not conducive to the conversion of HBeAg serology.In addition,it will increase the HCC risk of patients（especially patients with cirrhosis）,which is not conducive to the prognosis of patients.Therefore,low-level viremia in CHBexperienced patients has become a clinical issue of great concern.Aim: The aim of this study was to identify the characteristics and related factors for chronic hepatitis B patients with low-level viremia（LLV）after NAs treatment.Methods: We performed a retrospective study.The outpatients with CHB who had received NAs（ETV、TDF、TAF）treatment for 48±2 weeks in our hospital were recruited.Two groups were set in this study including LLV group（20IU/ml |
PDF Full Text Request